Evommune CSO sells 16,687 shares, exercises options

Evommune, Inc. Chief Scientific Officer Jeegar Pravinkumar Patel reported an exercise-and-sale transaction in company stock.

Rhea-AI Filing Summary

Evommune, Inc. Chief Scientific Officer Jeegar Pravinkumar Patel reported an exercise-and-sale transaction in company stock. He exercised employee stock options to acquire 13,512 shares of common stock at a price of $3.84 per share, then sold 16,687 shares of common stock at a weighted average price of $22.74 per share in open-market transactions pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2026. Following these transactions, he directly holds 46,403 shares of common stock and 29,330 employee stock options that remain outstanding and exercisable into common stock.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Patel Jeegar Pravinkumar

Role Chief Scientific Officer

Sold 16,687 shs ($379K)

Approx. gross sale proceeds $379K

Approx. exercise cost $52K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy)	13,512	$0.00	$0.00
Exercise	Common Stock	13,512	$3.84	$52K
Sale	Common Stock	16,687	$22.74	$379K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 29,330 contracts (Direct); Common Stock — 46,403 shares (Direct)

Footnotes (3)

1. F1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
3. F3. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Shares sold: 16,687 shares Weighted average sale price: $22.74 per share Sale price range: $22.50 to $23.35 +4 more

7 metrics

Shares sold 16,687 shares Common stock sold in open-market transactions on June 1, 2026

Weighted average sale price $22.74 per share Common stock sale on June 1, 2026

Sale price range $22.50 to $23.35 Range of prices for multiple sale transactions

Options exercised 13,512 shares Employee stock options exercised into common stock

Option exercise price $3.84 per share Employee Stock Option (Right to Buy) exercise

Common shares held after 46,403 shares Direct common stock ownership after transactions

Options remaining after 29,330 options Employee stock options outstanding following exercise

Key Terms

Rule 10b5-1 trading plan, weighted average price, Employee Stock Option (Right to Buy), option award vest

4 terms

Rule 10b5-1 trading plan regulatory

"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Employee Stock Option (Right to Buy) financial

"Employee Stock Option (Right to Buy)"

option award vest financial

"One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Evommune (EVMN) report for its Chief Scientific Officer?

Evommune’s Chief Scientific Officer, Jeegar Pravinkumar Patel, exercised employee stock options for 13,512 common shares at $3.84 and sold 16,687 common shares at a weighted average price of $22.74, all on June 1, 2026.

How many Evommune (EVMN) shares did the CSO sell and at what price?

The Chief Scientific Officer sold 16,687 shares of Evommune common stock at a weighted average price of $22.74 per share, with individual trades executed between $22.50 and $23.35 inclusive, in open-market transactions.

Were the recent Evommune (EVMN) insider sales made under a Rule 10b5-1 plan?

Yes. The reported sales of 16,687 Evommune common shares were executed pursuant to a Rule 10b5-1 trading plan that Jeegar Pravinkumar Patel adopted on February 27, 2026, indicating the transactions were pre-arranged rather than timed discretionarily.

How many Evommune (EVMN) shares does the CSO hold after the reported transactions?

After exercising options and selling shares, Evommune’s Chief Scientific Officer directly holds 46,403 shares of common stock and 29,330 employee stock options that remain outstanding and are exercisable into additional common shares, according to the filing.

What stock options did the Evommune (EVMN) CSO exercise in this Form 4?

He exercised employee stock options covering 13,512 shares of Evommune common stock at an exercise price of $3.84 per share. The option vests over four years, with one quarter vesting after one year and the rest in 36 monthly installments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 08:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Jeegar Pravinkumar

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1891 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		M(1)		13,512	A	$3.84	63,090	D
Common Stock	06/01/2026		S(1)		16,687	D	$22.74(2)	46,403	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$3.84	06/01/2026		M(1)			13,512	(3)	05/11/2033	Common Stock	13,512	$0.00	29,330	D

Explanation of Responses:

1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

3. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)